SCHEMBL23419650

SCHEMBL23419650

CCn1c(C(O)c2ccc(OC)cc2Cl)cn(Cc2nc3ccc(Cl)nc3[nH]2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 5/20 0.51
▸ S1PR1 P21453 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CRHR1 P34998 2/20 0.32
▸ P2RX7 Q99572 1/20 0.31
▸ P2RX3 P56373 3/20 0.31
▸ BRS3 P32247 1/20 0.31
▸ ACSS2 Q9NR19 1/20 0.31
▸ TPH1 P17752 1/20 0.31
▸ TPH2 Q8IWU9 1/20 0.31
▸ ADORA3 P0DMS8 1/20 0.31
▸ TUBB4A P04350 1/20 0.31
▸ TUBB P07437 1/20 0.31
▸ TUBA3C P0DPH7 1/20 0.31
▸ TUBA1B P68363 1/20 0.31
▸ TUBA4A P68366 1/20 0.31
▸ TUBB4B P68371 1/20 0.31
▸ TUBB3 Q13509 1/20 0.31
▸ TUBB2A Q13885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23419242 0.90 MARS2 (0.48) MARS2LMNAP2RX3
SCHEMBL20596079 0.87 MARS2 (0.68) MARS2ALDH1A1LMNACRHR1PRMT5
SCHEMBL23391548 0.83 MARS2 (0.40) MARS2P2RX3
SCHEMBL30145327 0.83 MARS2 (0.40) MARS2P2RX3
SCHEMBL23419421 0.82 MARS2 (0.52) MARS2S1PR1ALDH1A1BRS3ADORA3
SCHEMBL30145277 0.81 MARS2 (0.40) MARS2P2RX3
SCHEMBL23391444 0.81 MARS2 (0.40) MARS2P2RX3
SCHEMBL23419282 0.81 MARS2 (0.76) MARS2S1PR1P2RX7BRS3ADORA3
SCHEMBL20595924 0.76 MARS2 (0.66) MARS2PRMT5
SCHEMBL23419718 0.73 MARS2 (0.77) MARS2P2RX7BRS3ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885S1PR1 2805/4885ALDH1A1 1461/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885S1PR1 3673/4885ALDH1A1 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback